RxDoctor Payments Data

Supritha Shetty, MD

Internal Medicine · Mc Murray, PANPI 1164410585

Payments from drug & device makers

$7,000in general payments, 2019–2025

Across 420 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Pfizer$1K
  • Lilly USA, LLC$613
  • Abbott$334
  • Novo Nordisk$270
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,985100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,000 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$122,080
Medicare patients
236
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$168,154
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$101,588
JardianceEmpagliflozin99$97,529
OzempicSemaglutide51$56,701
MounjaroTirzepatide50$55,811
MyrbetriqMirabegron61$41,378
TrulicityDulaglutide23$33,103
XareltoRivaroxaban33$28,187
RybelsusSemaglutide11$23,007
AbrysvoRsv Vacc, Pref A And Pref B/Pf68$21,835
EntrestoSacubitril/Valsartan23$19,900
JanuviaSitagliptin Phosphate14$18,915
ProliaDenosumab11$18,273
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,431
Breo ElliptaFluticasone/Vilanterol12$7,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$1,120$189,989242 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$1,129$122,567189 claims
Boehringer IngelheimJardiance$214$97,52999 claims
Lilly USA, LLCMounjaro, Trulicity$613$88,91473 claims
Novo NordiskOzempic, Rybelsus$270$79,70862 claims
Astellas Pharma US IncMyrbetriq$187$41,37861 claims
Johnson & JohnsonXarelto$116$28,18733 claims
NovartisEntresto$47$19,90023 claims
MerckJanuvia$128$18,91514 claims
AmgenProlia$108$18,27311 claims
AbbVieSynthroid$1,499$2,01438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →